Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Ruxolitinib & Chronic graft-versus-host disease (cGVHD), Ruxolitinib is approved for chronic graft‑versus‑host disease (cGVHD) by both the FDA and EMA, with somewhat differing details (1).
The clinical phase III trial identified as NCT03112603 demonstrated that for patients suffering from glucocorticoid-refractory or glucocorticoid-dependent Chronic graft-versus-host disease (cGVHD), the use of ruxolitinib resulted in notably improved overall response, failure-free survival, and symptom response. However, it was also observed that the occurrence…